Biomarkers Predictive of Therapeutic Benefit 1

• 1008 · PDF Effect of the KRAS G12C inhibitor MK-1084 on circulating tumor DNA levels in participants with KRAS G12-mutated tumors Carlos Rojas, Matteo Simonelli, Adrian Sacher, Mehmet Ali Sendur, Rafal Dziadziuszko, Joon Oh Park, Victor Moreno Garcia, Jair Bar, Yun Fan, Mustafa Erman, Shun Lu, Jenny H. Lee, Rosalyn A. Juergens, Bangwei Cao, Cai Chen, Razvan Cristescu, Thomas Jemielita, Yewon Sofia Choi, Mark D. Ayers, Iwona Lugowska
• 1009 · PDF Landscape of homozygous copy number (CN) losses with established and emerging clinical actionability across 430,467 pan-tumor tissue samples Timothy A. Yap, Jessica K. Lee, Xin Liu, Erica Gornstein, Amaya Gasco, Richard S. P. Huang, Alexa B. Schrock
• 1010 · PDF DNA-level complex fusions show high discordance with RNA expression: A validation study of 115 Chinese cases Xinyue Wang, Lu Zhang, Xinyan Li, He Jiang, Jiayi Zhao, Richeng Jiang
• 1011 · PDF Correlation of mitophagy related genes expression and clinical outcome in metastatic colorectal cancer patients enrolled in CALGB (Alliance)/SWOG 80405 Shivani Soni, Yan Yang, Michela Bartolini, Pooja Mittal, Fang-Shu Ou, Lesly Torres-Gonzalez, Unnati Hemant Shah, Jae Ho Lo, Steve Soto Trujillo, Yitzhar Goretsky, Wu Zhang, Alan P. Venook, Sandra Algaze, Joshua Millstein, Heinz-Josef Lenz
• 1012 · PDF Multi-omic method to detect MTAP homozygous deletions enables high sensitivity detection from blood samples Geethika Yalamanchili, Sean Gordon, Evan Warner, Shile Zhang, Keelia Clemens, Matthew Ellis, Vishnu Ramani, Marisa Juntilla, Martina Lefterova, Justin Odegaard, Darya Chudova
• 1013 Immune microenvironment driven immunotherapy resistance in 11q13-amplified hepatocellular carcinoma Weiping Zhu
• 1014 · PDF Multimodal AI predicts immune checkpoint inhibitor response from clinically available inputs and whole-slide images with explainable tumor biology and combination therapy insights Felicia Kuperwaser, Sunil Kumar, Sepideh Foroutan, Dillon Tracy, Kevin Freisen, Taylor Wood, Zong Miao, Nathaniel Tann, Fahad Khan, Jean Michel Rouly, Anshu Jain, Jeff Sherman, Emily Vucic, Maayan Baron
• 1015 · PDF Quantitative c-MET immunohistochemistry reveals prognostic subgroups in papillary renal cell carcinoma Yong Il Lee, Jamin Park, Sun Young Yoon, Yong Mee Cho, Inkeun Park, Bokyung Ahn
• 1016 · PDF PHIT score integrates tumor biology to predict PDAC prognosis and therapy response Derek Erstad, Alejandro Zulbaran y Rojas, Christy Chai, Eugene Choi, George Van Buren, E. Ramsay Camp, William E. Fisher, Natalie Vokes
• 1017 · PDF STAT5A promoter hypermethylation as a biomarker of immune checkpoint inhibitor response in squamous cell carcinoma in cfDNA liquid biopsies Janice Patterson, Brooke Overstreet, Jiemin Liao
• 1018 · PDF Longitudinal peripheral blood TCR tracking predicts response to immune checkpoint inhibitors Dingyuan Wang, Kaiyan Xu, Parker J. Li, David J. H. Shih, Matthew K. L. Chiu, Jason W. H. Wong, Wei Dai, Aya El Helali
• 1020 · PDF Characterization of functional estrogen receptor (ER) dependence via comprehensive epigenomic liquid biopsy stratifies endocrine therapy (ET) responders with metastatic breast cancer (MBC) Stefania Morganti, Jonathan Beagan, Ningxuan (Shirley) Zhou, Khoi Nguyen, Kalie Smith, Ashka Patel, Catherine Stever, Katheryn Santos, Molly Skeffington, Olivia D'Amico, Travis Clark, Justin Finkle, Anthony D'Ippolito, Mike Zhong, Jamey Guess, Kristian Cibulskis, Aparna Gorthi, Tyrone Tamakloe, Charlene O'Brien, Baovy Tran, Mary McGillicuddy, Nabihah Tayob, Sara M. Tolaney, Nancy U. Lin, Hillary Heiling, Corrie A. Painter, Matthew L. Eaton, J. Carl Barrett, Heather A. Parsons
• 1021 · PDF Detection of rare genomic fusions revealed through comprehensive genomic profiling of atypical tumors Jennifer B. Jackson, Stanislav Fridland, Behtash G. Nezami, Gunja Pathak, Jennifer Dickey, Lawrence Jennings
• 1022 · PDF NFKBIA amplification attenuates B2M expression in NKX2.1-amplified lung adenocarcinoma, indicating immune evasion potential Ka Yee Li, Anthony J. Iafrate
• 1023 · PDF Ki67-kinetics and tumor biology shifts during neoadjuvant letrozole and ribociclib in ER-pos./HER2-neg. breast cancer: Insights from the NEOLETRIB-trial Julius Johannes Grindahl Hettich, Kamilla Fjermeros, Stephanie Beate Geisler, Manouchehr Seyedzadeh, Xavier Tekpli, Vessela N. Kristensen, Elin Edda Seland Agustsdottir, Unn-Cathrin Edvardsen Buvarp, Marie Fongaard, Tatiana Bosnjak-Olsen, Oeyvind Sundby, Alina Carmen Porojnicu, Helle Kristine Skjerven, Tone Hovda, Kristine Kleivi Sahlberg, Andliena Tahiri, Torben Lüders, Lilly Anne Torland, Silje Mathiassen, Sofie Flovik Ranestad, John Christopher Noone, Elma Bahonjic Hönigsperger, Clara Hammarstrøm, Jürgen Geisler
• 1024 · PDF CIN signatures as biomarkers of drug sensitivity: Real-world evidence from DNA targeted sequencing data David Gómez-Sánchez, Adam Price, Max Schmidt, Sharafudeen Abubakar, Farheen Shah, Christina Lee, Chin-Tung Chen, Barbara Hernando, Daniel Muldoon, Areej Alsaafin, Evan Seffar, George Li, Subhiksha Nandakumar, Wassim Abida, Stephen Graves, Mackenzie Sullivan, Rachel N. Grisham, Britta Weigelt, Luc GT Morris, Nadeem Riaz, Pedram Razavi, Allison L. Richards, Mark Donoghue, Walid Khaled Chatila, Chaitanya Bandlamudi, Nikolaus Schultz, Michael F. Berger, Sohrab Shah, Geoff Macintyre, Julio Garcia-Aguilar, Francisco Sanchez-Vega
• 1025 · PDF Monitoring PD-L1 in tumor macrophage fusion cells in blood correlates to PD-L1 checkpoint inhibitor responses in metastatic breast cancer Sonia Muthuraj, Massimo Cristofanilli, Carolina Reduzzi, Giuseppe Del Priore, William V. Williams, Cha-Mei Tang, Daniel L. Adams
• 1026 · PDF The copy number amplification of MYCL indicated activation of angiogenesis in small cell lung cancer Zihang Yuan, Jingwei Zhang, Yan Ju, Xingyuan Wu, Mantang Qiu, Xiao Li
• 1027 · PDF A robust predictive marker of clinical outcomes to immune-checkpoint inhibition in advanced squamous head-and-neck cancer calculated from histopathological slides Yaron Kinar, Tien-Hua Chen, Gal Dinstag, Ranit Aharonov, Tuvik Beker, Johnathan Arnon, Anna Elia, Aron Popovtzer, Changsu Lawrence Park, Carlos Diego H. Lopes, Muh-Hwa Yang
• 1028 · PDF A tumor-agnostic YAP/TAZ score predicts TEAD inhibitor sensitivity independent of Hippo alterations Michael Wegert-Verhoeven, Mathea Fransisca, Sylvia Martin, Attila Jady, Daniela Richter, Malgorzata Oles, Timon A. Blindauer, Jan-Philipp Mallm, Jasmina Paluncic, Claudia Dagostino, Olga Ermakova, Annika Schneider, Matthew The, Annika Baude-Müller, Katja Beck, Maximilian Bullemer, Victor Didier Perez Meza, Vivek Venkataramani, Ralf C. Bargou, Heiko Becker, Melanie Boerries, Armin Tuchscherer, DKFZ/NCT/DKTK MASTER consortium, Martin Wermke, Andreas Brunschweiger, Mohammed Al-Saeedi, Dirk Jäger, Olaf Witt, Denis Schapiro, Bernhard Küster, Andreas Hartig, Michael Allgaeuer, Alexander Brobeil, Christoph E. Heilig, Maria Veronica Teleanu, Simon Kreutzfeldt, Peter Horak, Daniel Hübschmann, Wolfgang Hartmann, Marcel Trautmann, Ina Oehme, Claudia R. Ball, Stefan Fröhling, Stefan M. Pfister, Hanno Glimm, Sebastian M. Dieter

在完整检索应用中浏览本分会场 →